10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Privately-held US firm ProThera Biologics and Japan’s largest drugmaker Takeda have entered into a global licensing agreement to develop a novel plasma-derived Inter-alpha Inhibitor Proteins (IAIP) therapy for the treatment of acute inflammatory conditions 23 April 2020
The China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) of the precision therapy avapritinib for two indications. 23 April 2020
Nerlynx (neratinib), a new breast cancer drug shown to significantly reduce the risk of cancer recurrence, is now commercially available to Singapore patients. 23 April 2020
Canadian biotech Quest PharmaTech saw its shares tumble 15.4% to C$0.11 by close of trading on Wednesday, after the company revealed that its subsidiary, OncoQuest, was divesting assets. 23 April 2020
Biogen has reported revenue of $3.5 billion for the first quarter of 2020, up 1%, with income at $1.4 billion or $8.08 per share, up from $7.15 per share. 22 April 2020
Germany’s Merck KGaA today announced a second Carlsbad, California, USA-based facility for its BioReliance viral and gene therapy service offering, with the company noting that the new 100 million-euro ($109 million) commercial facility is expected to open next year. 22 April 2020
Avacta has announced that, in only four weeks and well ahead of schedule, it has successfully generated multiple Affimer reagents that bind the SARS-COV-2 viral antigen. 22 April 2020
Cellphire says the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services, has exercised its third contract option. 22 April 2020
Volatility in some markets due to the COVID-19 pandemic had limited impact on business performance in the first quarter of 2020, said Swiss pharma giant Roche, which this morning reported group sales of 15.14 billion Swiss francs ($15,67 billion), showing growth of 2% (7% at constant exchange rates). 22 April 2020
A new collaboration in immuno-oncology will see Kite, a subsidiary of California’s Gilead Sciences, join forces with Melbourne-based oNKo-innate. 22 April 2020
Myovant Sciences has submitted a New Drug Application (NDA) to the US Food and Drug Administration for once-daily, oral relugolix (120mg) for the treatment of men with advanced prostate cancer. 22 April 2020
The UK government has announced a £1.25 billion ($1.56 billion) support package for innovative businesses during the coronavirus outbreak. 21 April 2020
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics have announced positive top-line data from the Phase III KALM-2 study of Korsuva (CR845/difelikefalin). 21 April 2020
New data published today in Neurology, the medical journal of the American Academy of Neurology, build on existing clinical evidence that Mayzent (siponimod) has proven to slow physical disability progression and provide cognitive benefits in people living with secondary progressive multiple sclerosis (SPMS). 21 April 2020
Shares in Boston, USA-based Alexion Pharmaceuticals rose over 3% on Monday, after the firm announced plans for a Phase III study of Ultomiris (ravulizumab-cwvz) in COVID-19. 21 April 2020
Dutch drugmaker Pharming has described as “encouraging” results from a study of Ruconest (recombinant human C1 inhibitor) in five people with severe pneumonia and COVID-19. 21 April 2020
A UK High Court ruling has invalidated patents held by San Francisco-based FibroGen, clearing the way for Akebia Therapeutics to proceed with a new class of medicine to treat anemia. 20 April 2020
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024